Aadi Bioscience, Inc. (AADI) Tops Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Aadi Bioscience Announces Financial Results for the Third Quarter of 2022 and Provides Corporate Update
November 9, 2022 8:01 AM ESTCompleted $72.5 million PIPE financing extending cash runway into 2025
PRECISION 1 trial on-track with preliminary data expected in the first half of 2023
24% revenue growth of FYARRO® (nab-sirolimus) over the second quarter 2022
Appointment of Neil Desai to Executive Chairman and transition of Brendan Delaney to CEO effective January 1, 2023
Conference call to be held today at 8:30 am ET
LOS ANGELES, Nov. 9, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:... More
